• In early January 2026, Axon Vision announced it had received an order from Leonardo DRS for new AI-enabled counter-unmanned aerial systems to support U.S. defense and homeland security forces, with the systems set for operational evaluations across manned and unmanned platforms.
• These AI-based counter-drone systems deepen the cooperation between Leonardo DRS and Axon Vision, highlighting Leonardo DRS’s push to pair its advanced sensing and integration capabilities with third-party artificial intelligence for enhanced situational awareness and force protection.
• We’ll now examine how this AI-focused counter-UAS order with Axon Vision may influence Leonardo DRS’s investment narrative around defense modernization.

Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Leonardo DRS Investment Narrative Recap

To own Leonardo DRS, you need to believe in sustained demand for advanced sensing, computing and force protection as defense customers modernize. The Axon Vision counter‑UAS order fits this thesis by sharpening DRS’s role in AI-enabled threat detection, but it does not materially change the near term focus on execution in core programs or the ongoing risk from concentrated U.S. government contracts.

The most relevant related development is the appointment of long-time executive Sally A. Wallace as Chief Operating Officer in January 2026. For investors watching DRS’s push into AI-driven systems and counter‑UAS solutions, stable, experienced operational leadership may matter for delivering on modernization opportunities while managing integration and partnership execution risks across its growing portfolio.

Yet investors should also be aware that heavy reliance on large U.S. defense contracts could become a problem if...

Leonardo DRS' narrative projects $4.1 billion revenue and $351.1 million earnings by 2028. This requires 6.6% yearly revenue growth and about a $101 million earnings increase from $250.0 million today.

Uncover how Leonardo DRS' forecasts yield a $47.30 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Seven members of the Simply Wall St Community currently estimate fair value for Leonardo DRS between US$24 and US$50, highlighting wide disagreement among private investors. Against that backdrop, the company’s push into AI-enabled counter‑UAS capabilities sits alongside an ongoing risk that shifts in U.S. defense budgets could affect future contract visibility and performance, so it is worth weighing several of these viewpoints before deciding how you see the stock.

Explore 7 other fair value estimates on Leonardo DRS - why the stock might be worth as much as 18% more than the current price!

Build Your Own Leonardo DRS Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Leonardo DRS research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Leonardo DRS research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Leonardo DRS' overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• AI is about to change healthcare. These 108 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.